Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bennouna

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
Revue Des Maladies Respiratoires|June 9, 2016
[Bevacizumab in combination with first-line treatment for metastatic non-small cell lung cancer in clinical practice. Results of the EOLE study]C Chouaid, L Falchero, R Schott, et al.
American Journal of Clinical Oncology|January 22, 2002
Resection of hepatic and pulmonary metastases in patients with colorectal cancerA Hamy, O Baron, J Bennouna, et al.
Journal of Medical Economics|November 13, 2013
Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancerT Rautenberg, U Siebert, D Arnold, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 17, 2004
Thyroglobulin monitoring after treatment of well-differentiated thyroid cancerA Hamy, E Mirallié, J Bennouna, et al.
Cancer Immunology, Immunotherapy : CII|April 27, 2000
Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancerJ Y Douillard, J Bennouna, F Vavasseur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2002
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II studyP Rougier, D Lepille, J Bennouna, et al.
Cancer Chemotherapy and Pharmacology|November 14, 2013
Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancerM Krzakowski, J Bennouna, E Dansin, et al.
ESMO Open|January 20, 2022
11 ESMO 2021 breakthroughs: practicing oncologist's perceptions on data presentationH K van Halteren, A Tan, B Pellegrino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumoursJ Bennouna, P Fumoleau, J-P Armand, et al.
Investigational New Drugs|September 22, 2012
Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunctionJ P Delord, A Ravaud, J Bennouna, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Revue Des Maladies Respiratoires|June 9, 2016
[Bevacizumab in combination with first-line treatment for metastatic non-small cell lung cancer in clinical practice. Results of the EOLE study]C Chouaid, L Falchero, R Schott, et al.
American Journal of Clinical Oncology|January 22, 2002
Resection of hepatic and pulmonary metastases in patients with colorectal cancerA Hamy, O Baron, J Bennouna, et al.
Journal of Medical Economics|November 13, 2013
Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancerT Rautenberg, U Siebert, D Arnold, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 17, 2004
Thyroglobulin monitoring after treatment of well-differentiated thyroid cancerA Hamy, E Mirallié, J Bennouna, et al.
Cancer Immunology, Immunotherapy : CII|April 27, 2000
Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancerJ Y Douillard, J Bennouna, F Vavasseur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2002
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II studyP Rougier, D Lepille, J Bennouna, et al.
Cancer Chemotherapy and Pharmacology|November 14, 2013
Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancerM Krzakowski, J Bennouna, E Dansin, et al.
ESMO Open|January 20, 2022
11 ESMO 2021 breakthroughs: practicing oncologist's perceptions on data presentationH K van Halteren, A Tan, B Pellegrino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumoursJ Bennouna, P Fumoleau, J-P Armand, et al.
Investigational New Drugs|September 22, 2012
Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunctionJ P Delord, A Ravaud, J Bennouna, et al.
Pageof 6